<DOC>
	<DOCNO>NCT02307851</DOCNO>
	<brief_summary>The purpose study determine immune response three dose level Quadrivalent VLP vaccine healthy young ( 18-49 ) adult . The study break four treatment group . Each group enroll 100 subject , total 400 subject . Groups A-C receive one three dose level Quadrivalent VLP vaccine , Group D receive commercially available trivalent influenza vaccine ( TIV ) . The study also evaluate safety tolerability Quadrivalent VLP vaccine formulation .</brief_summary>
	<brief_title>Quadrivalent Influenza VLP Vaccine Dose Ranging Study Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy adult male female , 1849 year age 2 . Willing able give inform consent prior study enrollment 3 . Able comply study requirement 4 . Women childbearing potential must negative urine pregnancy test vaccination , advise Informed Consent process avoid become pregnant duration study , must assert employ effective form birth control duration study . Acceptable form birth control : credible history continuous abstinence heterosexual activity , prior surgical sterilization , hormonal contraceptive ( oral , injectable , implant , patch , ring ) , barrier contraceptive ( condom diaphragm ) , intrauterine device ( IUD ) . Women adequately document history surgical sterility exempt urine pregnancy test . 1 . Any ongoing , symptomatic acute chronic illness require medical surgical care . Asymptomatic condition finding ( e.g. , mild hypertension , dyslipidemia ) associate evidence endorgan damage exclusionary provide appropriately manage clinically stable ( i.e. , unlikely result symptomatic illness within timecourse study ) opinion investigator . Acute chronic illness condition may reasonably predict become symptomatic treatment withdrawn interrupt exclusionary , even stable . Acute chronic illness reasonably expect associate increased risk associate influenza ( e.g. , cardiopulmonary disease , diabetes mellitus , renal hepatic dysfunction , hemoglobinopathy ) exclusionary , even stable . Note illness condition may exclusionary , even otherwise stable , due therapy use treat ( see exclusion criterion 2,5,8,9 ) . 2 . Participation research involve investigational product ( drug/ biologic/ device ) within 45 day plan date first vaccination 3 . History serious reaction prior influenza vaccination , know allergy constituent license TIV ( e.g. , egg protein ) polysorbate80 . 4 . History GuillainBarré Syndrome ( GBS ) within 6 week follow previous influenza vaccine . 5 . Received vaccine 4 week precede study vaccination influenza vaccine within six month precede study vaccination . 6 . History receipt avian influenza vaccine contain H5 antigen , know exposure bird infect H5 virus . 7 . Any known suspected immunosuppressive illness , congenital acquire , base medical history and/or physical examination . 8 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose great equal 10mg prednisone per day equivalent . The use topical , inhaled , nasal glucocorticoid permit . 9 . Administration immunoglobulins and/or blood product within three month precede administration study vaccine study . 10 . Acute disease time enrollment ( define presence moderate severe illness without fever , oral temperature &gt; 38.0°C planned day vaccine administration . 11 . Any condition opinion investigator would pose health risk subject enrol could interfere evaluation vaccine interpretation study result ( include neurologic psychiatric condition deem likely impair quality safety reporting ) . 12 . Known disturbance coagulation . 13 . Women breastfeed plan become pregnant study . 14 . Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>